Similar articles for PMID: 19282348

Year	Number of Results
1996	1
1999	1
2001	3
2003	3
2005	2
2006	3
2007	2
2008	8
2009	19
2010	15
2011	16
2012	21
2013	22
2014	15
2015	21
2016	20
2017	7
2018	10
2019	12
2020	8
2021	6
2022	18
2023	4
2024	0

1

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.

Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C; TBNET Study Group. Migliori GB, et al. Eur Respir J. 2009 Aug;34(2):387-93. doi: 10.1183/09031936.00009509. Epub 2009 Mar 12. Eur Respir J. 2009. PMID: 19282348 Free article.

2

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

Koh WJ, Kwon OJ, Gwak H, Chung JW, Cho SN, Kim WS, Shim TS. Koh WJ, et al. J Antimicrob Chemother. 2009 Aug;64(2):388-91. doi: 10.1093/jac/dkp171. Epub 2009 May 25. J Antimicrob Chemother. 2009. PMID: 19468028 Free article.

3

Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients.

Koh WJ, Kang YR, Jeon K, Kwon OJ, Lyu J, Kim WS, Shim TS. Koh WJ, et al. J Antimicrob Chemother. 2012 Jun;67(6):1503-7. doi: 10.1093/jac/dks078. Epub 2012 Mar 8. J Antimicrob Chemother. 2012. PMID: 22403262 Free article.

4

Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand.

Roongruangpitayakul C, Chuchottaworn C. Roongruangpitayakul C, et al. J Med Assoc Thai. 2013 Oct;96(10):1273-82. J Med Assoc Thai. 2013. PMID: 24350407

5

Linezolid in the treatment of MDR-TB: a retrospective clinical study.

Xu HB, Jiang RH, Li L, Xiao HP. Xu HB, et al. Int J Tuberc Lung Dis. 2012;16(3):358-63. doi: 10.5588/ijtld.11.0493. Int J Tuberc Lung Dis. 2012. PMID: 22640450

6

Linezolid in the treatment of multidrug-resistant tuberculosis.

Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Schecter GF, et al. Clin Infect Dis. 2010 Jan 1;50(1):49-55. doi: 10.1086/648675. Clin Infect Dis. 2010. PMID: 19947856

7

Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

De Lorenzo S, Alffenaar JW, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Bolhuis MS, van Altena R, Viggiani P, Piana A, Spanevello A, Migliori GB. De Lorenzo S, et al. Eur Respir J. 2013 Jun;41(6):1386-92. doi: 10.1183/09031936.00124312. Epub 2012 Sep 20. Eur Respir J. 2013. PMID: 22997218 Free article.

8

Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

Anger HA, Dworkin F, Sharma S, Munsiff SS, Nilsen DM, Ahuja SD. Anger HA, et al. J Antimicrob Chemother. 2010 Apr;65(4):775-83. doi: 10.1093/jac/dkq017. Epub 2010 Feb 11. J Antimicrob Chemother. 2010. PMID: 20150181

9

Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.

Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD, Shim TS. Park IN, et al. J Antimicrob Chemother. 2006 Sep;58(3):701-4. doi: 10.1093/jac/dkl298. Epub 2006 Jul 19. J Antimicrob Chemother. 2006. PMID: 16857689 Clinical Trial.

10

Multidrug- and extensively drug-resistant tuberculosis, Germany.

Eker B, Ortmann J, Migliori GB, Sotgiu G, Muetterlein R, Centis R, Hoffmann H, Kirsten D, Schaberg T, Ruesch-Gerdes S, Lange C; German TBNET Group. Eker B, et al. Emerg Infect Dis. 2008 Nov;14(11):1700-6. doi: 10.3201/eid1411.080729. Emerg Infect Dis. 2008. PMID: 18976552 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

216 results

Results by year